RE-LY Study Oversight Weaknesses A Factor In Pradaxa “Refuse-To-File” Action

Weaknesses in the oversight of the Pradaxa pivotal study by Boehringer Ingelheim GmbH and its contract research organization may have led to data quality problems that ultimately delayed FDA approval of the anticoagulant by four months.